Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Net Margin: 2019-2025

Historic Net Margin for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -286.43%.

  • C4 Therapeutics' Net Margin fell 12586.00% to -286.43% in Q3 2025 from the same period last year, while for Sep 2025 it was -395.51%, marking a year-over-year decrease of 8217.00%. This contributed to the annual value of -295.96% for FY2024, which is 34237.00% up from last year.
  • As of Q3 2025, C4 Therapeutics' Net Margin stood at -286.43%, which was up 28.86% from -402.60% recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Net Margin ranged from a high of -77.99% in Q4 2021 and a low of -1,348.42% during Q2 2023.
  • For the 3-year period, C4 Therapeutics' Net Margin averaged around -595.04%, with its median value being -402.60% (2025).
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by 115,413bps in 2023, then soared by 120,086bps in 2024.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Net Margin stood at -77.99% in 2021, then crashed by 88,249bps to -960.48% in 2022, then tumbled by 10,527bps to -1,065.75% in 2023, then spiked by 39,793bps to -667.82% in 2024, then crashed by 12,586bps to -286.43% in 2025.
  • Its Net Margin was -286.43% in Q3 2025, compared to -402.60% in Q2 2025 and -363.66% in Q1 2025.